Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

In This Article:

  • National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.

  • Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.

  • Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.[1],[2]

  • Elanco's ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco's commitment to increasing the availability of CPMA.

  • Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York have some of the highest reported cases of canine parvovirus outbreaks according to ParvoTrack.

GREENFIELD, IN / ACCESS Newswire / April 22, 2025 / Elanco Animal Health Incorporated (NYSE:ELAN) today recognizes the second annual National Parvo Awareness Day, aimed at increasing awareness of canine parvovirus, a highly contagious and often-fatal puppy disease. Since receiving conditional approval from the USDA, Canine Parvovirus Monoclonal Antibody (CPMA) has helped save thousands of puppies.[3] Although parvovirus can strike anytime, late spring and summer months are the most common for outbreaks nationwide.

"Parvo is a devastating disease that not only impacts our pets, but takes an emotional toll on pet owners, veterinarians and animal health experts," said Dr. Chris George, veterinarian and infectious disease expert at Elanco Animal Health. "Without supportive care, parvo has a 91% mortality rate.[4] However, there's a treatment beyond just supportive care - Elanco's CPMA which can help defend puppies and defeat parvo. In real-world usage, 93% of parvo-infected puppies treated with CPMA survived.[1] Additionally, parvo patients treated with CPMA spend an average of 1.87 less days in the hospital, helping to relieve the emotional toll on treating veterinary staff and getting pets back with their families. CPMA is changing the way we treat parvo and is helping save puppies across the country."[2]

Elanco's mission to save 1 million puppies from parvovirus by 2030

"Making CPMA widely available is crucial in our fight against this devastating virus, including in shelter environments where resources are often strained," said Bobby Modi, Executive Vice President, U.S. Pet Health. "Elanco is focused on increasing access to this life-saving treatment, and we've saved thousands of puppies in the first year[3] - but we need help from every clinic around the country to reach our mission of saving 1 million puppies from parvovirus by 2030. We believe every clinic and shelter should experience the power of CPMA firsthand, so we encourage clinics who haven't tried it to learn more about how they can save their first parvo puppy using CPMA."